Association between modified CHA$_2$DS$_2$-VASc Score with Ankle-Brachial index < 0.9

Po-Chao Hsu$^{1,2}$, Wen-Hsien Lee$^{1,2,3}$, Hsiang-Chun Lee$^{1,2}$, Wei-Chung Tsai$^{1,2}$, Chun-Yuan Chu$^{1,2}$, Ying-Chih Chen$^{1,3}$, Chee-Siong Lee$^{1,2}$, Tsung-Hsien Lin$^{1,2}$, Wen-Chol Voon$^{1,2}$, Sheng-Hsiung Sheu$^{1,2}$ & Ho-Ming Su$^{1,2,3}$

The ankle-brachial index (ABI) is a reliable diagnostic examination for peripheral arterial occlusive disease (PAOD). We previously reported CHADS2 score was significantly correlated with PAOD. However, the association between CHA2DS2-VASc score and ABI < 0.9 is not evaluated in the literature. The aim of the present study was to investigate whether CHA2DS2-VASc score has a strong association with PAOD. We enrolled 1482 patients in this study. PAOD was defined as ABI < 0.9 in either leg. Vascular disease in CHA2DS2-VASc score was modified as vascular disease except PAOD. Of the 1482 subjects, the prevalence of ABI < 0.9 was 5.6%. Multivariate analysis showed that the increased age, decreased estimated glomerular filtration rate and increased modified CHA2DS2-VASc score (OR, 1.764; $p < 0.001$) were independent associated with ABI < 0.9. In addition, the percentage of ABI < 0.9 in patients with modified CHA2DS2-VASc score of 0, 1, and < 2 were 0%, 0.9%, and 0.7%, respectively (All < 1%). Our study demonstrated modified CHA2DS2-VASc score was significantly associated with ABI < 0.9. Calculation of modified CHA2DS2-VASc score might be useful in identifying patients with PAOD and in stratifying the risk of PAOD in non-AF patients.
Discussion

In this study, we evaluated the association of ABI < 0.9 with modified CHA₂DS²-VASc score. We found that advanced age, lower eGFR, and modified CHA₂DS²-VASc score was independently associated with ABI < 0.9. In
ischemia, mortality rates could be as high as 20% within 6 months from diagnosis and exceeding 50% at 5 years9. The modified CHA2DS2-VASc score itself should have a strong correlation with PAOD. In the present study, we consistently demonstrated that modified CHA2DS2-VASc score was significantly associated with ABI < 0.9 in patient with asymptomatic and symptomatic PAOD. Several recent studies extended the usage of CHA2DS2-VASc score to non-AF population30–32. Mustafa Cetin et al. reported that CHA2DS2-VASc score was increased in patients with mild and severe CAD, and it was correlated significantly with the number of diseased vessels and Gensini score. Therefore, their findings suggested that CHA2DS2-VASc score might be useful in prediction of the risk of severe CAD30. Modi R et al. also found that CHADS2 score and CHA2DS2-VASc score correlated significantly with CAD severity and suggested these scores might play an important role in predicting the severity of CAD14. In addition, Hoshino T et al. reported that CHADS2 score > 2 and CHA2DS2-VASc score > 4 are associated with 3-month functional outcome of stroke in patients with prior coronary artery disease32.

Patients with PAOD have significantly increased cardiovascular morbidity and mortality. The 5-year mortality of patients with asymptomatic and symptomatic PAOD is 19% and 24%. However, in patients with critical limb ischemia, mortality rates could be as high as 20% within 6 months from diagnosis and exceeding 50% at 5 years9. Therefore, how to identify high risk and low risk patients become extremely important during initial diagnosis. Risk factors of PAOD include advanced age, diabetes, hypertension, stroke, heart failure, and so on6–10. Advanced age, diabetes, and hypertension were considered as traditional risk factors of PAOD. Because PAOD was a systemic atherosclerotic process and shares similar risk factors to atherosclerosis in the coronary and carotid arteries, there was also a strong association of PAOD with stroke and CAD11–13,16,17. Coexistent CAD and stroke were highly prevalent in patients with PAOD particularly in the elderly population7,17. Adesunloye BA et al. also showed patients with heart failure were over 3 times more likely to have PAOD compared to the general population14.

PAOD was more prevalent in women than generally appreciated. The estimates of PAOD varied greatly according to the different diagnostic criteria. PAOD was also be affected by different race15. According to a systematic review of global estimates of prevalence and risk factors for PAOD in 2000 and 2010, the association of sex with PAOD had an inconsistent result in the two setting. For all countries, female overall had a significantly higher risk than male, but in high income countries, male had an increased risk of PAOD than females18. In our previous nationwide cohort study of PAOD in Taiwan, female gender was found to be a significant predictor of new-onset PAOD after multivariate analysis20. Because the components of modified CHA2DS2-VASc score were significantly correlated with PAOD, modified CHA2DS2-VASc score itself should have a strong correlation with PAOD. In the present study, we consistently demonstrated that modified CHA2DS2-VASc score was significantly associated with ABI < 0.9 not only in the univariate analysis but also in the multivariate analysis. In addition, although CHADS2 score was significantly associated with ABI < 0.9 in the univariate analysis, the association disappeared in the multivariate analysis. Hence, modified CHA2DS2-VASc score might be more useful in identifying patients with PAOD than CHADS2 score.

### Table 2. Determinants of ABI < 0.9 in study patients. Values expressed as odds ratio (OR) and 95% confidence interval (CI). Abbreviations are the same as in Table 1.

| Parameter | Univariate OR (95% CI) | P | Multivariate (Forward) OR (95% CI) | P |
|-----------|-----------------------|---|------------------------------------|---|
| Age (per 1 year) | 1.088 (1.065–1.111) | <0.001 | 1.058 (1.017–1.101) | 0.005 |
| Male gender | 1.046 (0.670–1.634) | 0.842 | — | — |
| Smoking (ever versus never) | 0.671 (0.316–1.421) | 0.297 | — | — |
| Diabetes mellitus | 3.921 (2.492–6.169) | <0.001 | — | — |
| Hypertension | 2.406 (1.317–4.395) | 0.004 | — | — |
| Congestive heart failure | 3.930 (2.310–6.687) | <0.001 | — | — |
| Cerebrovascular disease | 3.188 (1.690–6.017) | <0.001 | — | — |
| Coronary artery disease | 2.294 (1.405–3.747) | 0.001 | — | — |
| Body mass index (per 1 kg/m²) | 0.891 (0.836–0.949) | <0.001 | — | — |
| CHADS2 score | 2.539 (2.097–3.074) | <0.001 | — | — |
| CHA2DS2-VASc score | 2.127 (1.826–2.477) | <0.001 | 1.764 (1.338–2.325) | <0.001 |
| eGFR (per 1 mL/min/1.73 m²) | 0.961 (0.951–0.971) | <0.001 | 0.977 (0.960–0.994) | 0.010 |
| Laboratory parameters |
| Triglyceride (mg/dL) | 1.000 (0.998–1.002) | 0.866 | — | — |
| Total cholesterol (mg/dL) | 1.002 (0.996–1.008) | 0.509 | — | — |
| Uric acid (mg/dL) | 1.150 (1.027–1.288) | 0.015 | — | — |
| Medications |
| Aspirin use | 2.012 (1.251–3.236) | 0.004 | — | — |
| ACEI use | 1.768 (0.986–3.171) | 0.056 | — | — |
| ARB use | 1.676 (1.073–2.617) | 0.023 | — | — |
| β-blocker use | 1.238 (0.794–1.932) | 0.346 | — | — |
| CCB use | 1.276 (0.814–1.999) | 0.287 | — | — |
| Diuretic use | 2.417 (1.547–3.777) | <0.001 | — | — |
| Statin use | 1.922 (1.333–3.262) | 0.015 | — | — |
Although CHADS₂ score was a useful and simple tool to estimate the risk of PAOD in our previous study¹⁹,²⁰, it still had the limitation to identify low-risk patients which is similar to its usage in AF patients for stroke and systemic embolism prediction. In our study, the percentage of ABI < 0.9 in patients with CHADS₂ score of 0 and 1 were 0.7% and 1.7%; however, the percentage of ABI < 0.9 in patients with CHA₂DS₂-VASc score of 0 and 1 were 0% and 0.9% which were both <1%. These results suggest that CHA₂DS₂-VASc score might be a more useful clinical tool for new-onset PAOD prediction and help physicians to further stratify the risk of PAOD than CHADS₂ score in non-AF patients.

The prevalence of ABI < 0.9 was 5.6% in our study. According to the previous literature, the prevalence of PAOD in Asia was less than 5% in the general population³³. In addition, Chen et al. also reported that overall prevalence of ABI < 0.9 in 1915 Taiwanese patients was 5.4%, which was also similar to our study³⁴.

Although there are several similar risk factors such as age, hypertension, diabetes, and heart failure between CHA₂DS₂-VASc score and stroke, CAD, and even PAOD, there still exists many dissimilarities between them. For example, when the predicted outcome is stroke, the definition of vascular disease of CHA₂DS₂-VASc score is prior myocardial infarction, PAOD, or aortic plaque. However, when the predicted outcomes is CAD, some studies define the vascular disease as the one used in stroke prediction³⁵, but some studies define the vascular disease as PAOD only³⁰,³¹. In the present study, we evaluated the association between PAOD and modified CHA₂DS₂-VASc score, so we defined the vascular disease as CAD only.

There were several limitations to our study. First, because our study was a cross-sectional one, we could only confirm the significant association of modified CHA₂DS₂-VASc score with ABI < 0.9. We could not elucidate the true cause-effect relationship between them. Second, since the subjects of this study were already being evaluated for heart disease, it was susceptible to selection bias and making findings potentially less generalized. Third, the majority of our patients were treated chronically with antihypertensive medications. For ethical reasons, we did not withdraw these medications and could not exclude the influence of antihypertensive agents on our findings. However, we had adjusted these parameters during multivariate analysis in our study.

In conclusion, our study demonstrated modified CHA₂DS₂-VASc score was significantly associated with ABI < 0.9. Calculation of modified CHA₂DS₂-VASc score might be useful in identifying patients with PAOD and in stratifying the risk of PAOD in non-AF patients. Future prospective study is needed to examine the ability of modified CHA₂DS₂-VASc score in prediction of newly-onset of PAOD.

Methods

Study subjects. Our study was a cross-sectional study. Study subjects were consecutively included from a group of patients who were arranged for echocardiographic examinations at Kaohsiung Municipal Hsiao-Kang Hospital. We excluded patients with significant aortic or mitral valve diseases, AF, and inadequate image visualization. Finally, a total of 1482 patients were included.
Ethics statement. The study methods were carried out in accordance with the approved guidelines. The study protocol was approved by the institutional review board committee of the Kaohsiung Medical University Hospital (KMUH-IRB-20130093). Informed consents have been obtained in written form from patients. All clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The patients gave consent for the publication of the clinical details.

ABI assessment. The values of ABI were measured by an ABI-form device (VP1000; Colin Co. Ltd., Komaki, Japan), which simultaneously and automatically measured blood pressures in both arms and ankles using an oscillometric method. The ABI was calculated by the ratio of the ankle systolic blood pressure divided by the higher systolic blood pressure of the arms. After obtaining bilateral ABI values, the lower one was used for later analysis. The ABI measurement was done once in each patient.

Collection of demographic, medical, and laboratory data. Demographic and medical data including age, gender, smoking history, and comorbid conditions were obtained from interviews or medical records of patients. The body mass index (BMI) was calculated as the ratio of weight in kilograms divided by square of height in meters. Laboratory data such as triglyceride, total cholesterol, and uric acid were measured from fasting blood samples. The value of estimated glomerular filtration rate (eGFR) was calculated using the equation in the Modification of Diet in Renal Disease (MDRD) study. In addition, medications of patients including aspirin, β-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), diuretics, and statins during the study period were obtained from medical records.

Assessment of CHADS2 score and modified CHA2DS2-VASc score. The CHADS2 score is derived from the sum of point values of individual risk factors: congestive heart failure, hypertension, age ≥75 years, diabetes (1 point each), and prior stroke (2 points). The modified CHA2DS2-VASc score is derived from the sum of point values of individual risk factors: congestive heart failure, hypertension, age between 65 and 74 years, diabetes, female sex, vascular disease except PAOD (1 point each), age ≥75 years (2 points), and prior stroke (2 points). Because the aim of current study was to evaluate the risk of PAOD, vascular disease in this study was modified as vascular disease except PAOD. Congestive heart failure was defined as left ventricular systolic dysfunction with left ventricular ejection fraction ≤40% or having a known history of congestive heart failure. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or anti-hypertensive drugs were prescribed. Diabetes was defined as fasting blood glucose level greater than 126 mg/dL or hypoglycemic agents were used to control blood glucose levels. Prior stroke was defined as history of cerebrovascular disease including cerebral bleeding and infarction.

Statistical analysis. The SPSS 18.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data are expressed as percentages or mean ± standard deviation. Categorical and continuous variables between groups were compared by independent Chi-square test and samples t-test, respectively. The relationship between variables and ABI < 0.9 was assessed by univariate regression analysis. Subsequently, significant variables in the univariate analysis were further analyzed by forward multiple logistic regression analysis to identify the parameters associated with ABI < 0.9. All tests were 2-sided, and the level of significance was established as p < 0.05.

References
1. Fowkes, F. G. et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemol 20, 384–392 (1991).
2. Hasimu, B. et al. Ankle brachial index as a marker of atherosclerosis in Chinese patients with high cardiovascular risk. Hypertens Res 29, 23–28, https://doi.org/10.1291/hypres.29.23 (2006).
3. Heald, C. L., Fowkes, F. G., Murray, G. D. & Price, J. F. & Ankle Brachial Index. C. Risk of mortality and cardiovascular disease associated with the ankle–brachial index: Systematic review. Atherosclerosis 189, 61–69, https://doi.org/10.1016/j.atherosclerosis.2006.03.011 (2006).
4. Hansen, N. M. et al. Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study. Diabetes Care 35, 1731–1735, https://doi.org/10.2337/dc12-0178 (2012).
5. Chen, S. C. et al. Ankle brachial index as a predictor for mortality in patients with chronic kidney disease and undergoing haemodialysis. Nephrology (Carlton) 15, 294–299, https://doi.org/10.1111/j.1440-1797.2010.01187.x (2010).
6. Bartholomew, J. R. & Olin, J. W. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 73(Suppl 4), S8–14 (2006).
7. Lee, W. H. et al. Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan. PLoS One 9, e92577, https://doi.org/10.1371/journal.pone.0092577 (2014).
8. Diehm, C. et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 120, 2053–2061, https://doi.org/10.1161/CIRCULATIONAHA.109.865600 (2009).
9. Abu Dabrh, A. M. et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg 62, 1642–1651 e1643, https://doi.org/10.1016/j.vasurg.2015.07.065 (2015).
10. Selvin, E. & Erlinger, T. P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110, 738–743, https://doi.org/10.1161/01.CIR.0000137913.26087.F0 (2004).
11. Banerjee, A., Fowkes, F. G. & Rothwell, P. M. Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. Stroke 41, 2102–2107, https://doi.org/10.1161/STROKEAHA.110.583627 (2010).
12. Meves, S. H. et al. Peripheral arterial disease as an independent predictor for excess stroke morbidity and mortality in primary-care patients: 5-year results of the getABI study. Cerebrovasc Dis 29, 546–554, https://doi.org/10.1159/000306640 (2010).
13. Topkian, R. et al. High prevalence of peripheral arterial disease in patients with acute ischaemic stroke. Cerebrovasc Dis 29, 248–254, https://doi.org/10.1159/000267850 (2010).
14. Adesunloye, B. A., Valadri, R., Moerue, N. M. & Onwuanyi, A. E. Impact of peripheral arterial disease on functional limitation in congestive heart failure: results from the national health and nutrition examination survey (1999–2004). Cardiol Res Pract 2012, 306852, https://doi.org/10.1155/2012/306852 (2012).
15. Mosca, L. et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 96, 2468–2482 (1997).
16. Hirsch, A. T. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286, 1317–1324 (2001).
17. Shammas, N. W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 3, 229–234 (2007).
18. Fowkes, F. G. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382, 1529–1534, https://doi.org/10.1016/S0140-6736(13)62490-0 (2013).
19. Hsu, P. C. et al. Association between the CHADS2 score and an ankle-brachial index of 0.9 in patients without atrial fibrillation. J Atheroscler Thromb 21, 322–328 (2014).
20. Hsu, P. C. et al. CHADS2 Score and Risk of New-onset Peripheral Arterial Occlusive Disease in Patients without Atrial Fibrillation: A Nationwide Cohort Study in Taiwan. J Atheroscler Thromb 22, 490–498, https://doi.org/10.5551/jat.27284 (2015).
21. Gage, B. F. et al. Validation of classical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864–2870 (2001).
22. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137, 263–272, https://doi.org/10.1378/chest.09-1584 (2010).
23. Camm, A. J. et al. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33, 2719–2747, https://doi.org/10.1093/eurheartj/ehs233 (2012).
24. January, C. T. et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, 2071–2104, https://doi.org/10.1161/CIR.0000000000000404 (2014).
25. Kirchhoff, P. et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37, 2893–2962, https://doi.org/10.1093/eurheartj/ehw210 (2016).
26. Chiang, C. E. et al. Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc 115, 893–952, https://doi.org/10.1016/j.jfma.2016.10.005 (2016).
27. Guo, Y. et al. Validation of contemporary stroke and bleeding risk stratification scores in non-antiocoagulated Chinese patients with atrial fibrillation. Int J Cardiol 168, 904–909, https://doi.org/10.1016/j.ijcard.2012.10.052 (2013).
28. Chao, T. F. et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians? Heart Rhythm 13, 46–53, https://doi.org/10.1016/j.hrthm.2015.08.017 (2016).
29. Siu, C. W., Lip, G. Y., Lam, K. F. & Tse, H. F. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation. J Formos Med Assoc 115, 1376–1383, https://doi.org/10.1016/j.jfma.2016.02.011 (2016).
30. Cetin, M. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130, 65–73, https://doi.org/10.1059/ajkd.2015.08.017 (2016).
31. Liu, H. et al. Peripheral arterial disease and clinical risks in Taiwanese hemodialysis patients. Angiology 61, 66–73, https://doi.org/10.1177/0003319793338671 (2010).
32. Chen, Y. J. et al. Prevalence of asymptomatic peripheral arterial disease and related risk factors in younger and elderly patients in Taiwan. Angiology 65, 396–401, https://doi.org/10.1177/0003319713480842 (2014).
33. Huang, F. Y. et al. CHADS2, CHA2DS2-VASc and R2CHADS2 scores predict mortality in patients with coronary artery disease. Intern Emerg Med 12, 479–486, https://doi.org/10.1007/s11739-017-1608-x (2017).
34. Yamashina, A. et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25, 359–364 (2002).
35. Tomyama, H. et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 166, 303–309 (2003).
36. Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130, 461–470 (1999).

Acknowledgements
The research presented in this article is supported by the grant from Kaohsiung Municipal Hsiao–Kang Hospital (kmhk-106-006), Kaohsiung Medical University, Kaohsiung, Taiwan.

Author Contributions
Po-Chao Hsu, Wen-Hsien Lee, and Ho-Ming Su drafted the manuscript. Hsiang-Chun Lee, Wei-Chung Tsai, Chun-Yuan Chu and Ying-Chih Chen prepared tables and assisted with the statistical analysis. Chee-Siong Lee, Tsung-Hsien Lin, Wen-Chol Voon, Sheng-Hsiung Sheu, and Ho-Ming Su conceived of the study and participated in its design and coordination. All authors have read and approved the final manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018